Genetic Signatures Ltd (ASX: GSS) Share Price and News

Price

$0.44

Movement

0.00 (0.0)

as at 6 Jun - Closed (20 mins delayed)

52 Week Range

$0.36 - $0.82

 
1 Year Return

-41.33%

Genetic Signatures Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $104.48 million
P/E Ratio 38.91
Dividend Yield 0.00%
Shares Outstanding 227.14 million
Earnings per share -0.104
Dividend per share N/A
Year To Date Return -28.57%
Earnings Yield 2.57%
Franking -
Share Price

$0.44

Day Change

0.00 (0.0)

52 Week Range

$0.36 - $0.82

Yesterday's Close

$0.44

Today's Open

Days Range

-

Volume

0

Avg. Volume (1 month)

69,299

Turnover

$0

as at 6 Jun - Closed

  • Genetic Signatures Ltd (ASX: GSS)
    Latest News

    Share Gainers

    Why Afterpay, Genetic Signatures, Qube, & Serko shares are charging higher

    Afterpay Ltd (ASX:APT) and Serko Ltd (ASX:SKO) shares are two of four surging higher on Friday. Here's what you need…

    Read more »

    GSS ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    30th Apr 2025 2025-04-30T10:12:13 Quarterly Activities/Appendix 4C Cash Flow ReportYesNo10:12am8333k
    28th Feb 2025 2025-02-28T15:10:34 Notification of cessation of securities - GSSYesNo3:10pm413k
    26th Feb 2025 2025-02-26T10:14:19 1H FY25 Market UpdateYesNo10:14am141.5M
    26th Feb 2025 2025-02-26T10:13:44 Positive Momentum For The First Half ResultYesNo10:13am4202k
    26th Feb 2025 2025-02-26T10:12:59 Half Yearly Report and AccountsYesNo10:12am22695k
    25th Feb 2025 2025-02-25T10:12:37 1H FY25 Results and Investor Webinar NotificationYesNo10:12am173k
    3rd Feb 2025 2025-02-03T11:41:55 Appointment of Joint Company SecretaryYesNo11:41am1211k
    3rd Feb 2025 2025-02-03T08:27:45 Appendix 3Y - Late Lodgement NoticeYesNo8:27am3398k
    31st Jan 2025 2025-01-31T09:24:08 Quarterly Activities/Appendix 4C Cash Flow ReportYesNo9:24am8293k
    17th Dec 2024 2024-12-17T08:31:30 Change of Director's Interest NoticeYesNo8:31am2135k

    About Genetic Signatures Ltd

    Genetic Signatures Limited is a molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, 3Base™

    GSS Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    04 Jun 2025 $0.46 $0.01 2.22% 15,830 $0.47 $0.47 $0.46
    03 Jun 2025 $0.45 $-0.04 -8.25% 8,554 $0.49 $0.49 $0.45
    02 Jun 2025 $0.49 $0.01 2.08% 4,306 $0.48 $0.49 $0.48
    29 May 2025 $0.48 $-0.07 -12.84% 116,903 $0.55 $0.55 $0.48
    28 May 2025 $0.55 $-0.01 -1.80% 45,229 $0.54 $0.55 $0.53
    27 May 2025 $0.56 $0.00 0.00% 26,388 $0.56 $0.56 $0.56
    26 May 2025 $0.56 $-0.02 -3.48% 827 $0.56 $0.56 $0.56
    22 May 2025 $0.58 $0.01 1.75% 35 $0.58 $0.58 $0.58
    21 May 2025 $0.57 $-0.02 -3.39% 8,470 $0.59 $0.59 $0.57
    20 May 2025 $0.59 $-0.01 -1.68% 49 $0.59 $0.59 $0.59
    19 May 2025 $0.60 $-0.01 -1.67% 17,420 $0.60 $0.60 $0.60
    16 May 2025 $0.60 $0.01 1.68% 673,914 $0.60 $0.60 $0.60
    15 May 2025 $0.60 $0.00 0.00% 9,790 $0.58 $0.60 $0.58
    14 May 2025 $0.60 $-0.01 -1.67% 24,838 $0.60 $0.60 $0.55
    13 May 2025 $0.60 $0.00 0.00% 78,538 $0.60 $0.64 $0.58
    12 May 2025 $0.60 $-0.05 -7.69% 142,306 $0.65 $0.65 $0.58
    09 May 2025 $0.65 $-0.03 -4.44% 50,916 $0.69 $0.69 $0.62
    08 May 2025 $0.68 $0.16 30.77% 172,300 $0.53 $0.68 $0.53
    07 May 2025 $0.52 $0.02 4.00% 33,605 $0.50 $0.52 $0.50
    06 May 2025 $0.50 $-0.02 -3.88% 37,813 $0.49 $0.50 $0.46

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    16 Dec 2024 Michael Aicher Issued 66,666 $49,999
    Issue of securities.
    06 Dec 2024 Neil Gunn Issued 500,000 $317,500
    Issue of options.
    08 Jul 2024 Stephane Chatonsky Issued 27,750 $20,812
    Rights issue.
    08 Jul 2024 Anthony (Tony) Radford Issued 47,439 $35,579
    Rights issue.
    08 Jul 2024 Caroline Waldron Issued 3,302 $2,476
    Rights issue.
    02 Jul 2024 Nicholas Samaras Buy 46,892 $35,169
    Off-market trade.
    02 Jul 2024 Nicholas Samaras Sell 46,892 $35,169
    Off-market trade.
    13 Jun 2024 Nicholas Samaras Issued 171,618 $128,713
    As advised by the company. Participation in the GSS Institutional Entitlement Offer.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Ms Caroline Waldron Non-Executive DirectorNon-Executive Chairman May 2022
    Ms Waldron is a cross-border advisor and director with over 30 years expertise in governance, marketing, human resources, and digital transformation across a range of sectors. Her formal training is in law, and she has been admitted to the Bar of England and Wales and the courts of other jurisdictions including Australia and New Zealand. She is a member of the Risk Committee.
    Dr Jenny Lee Harry Non-Executive Director Oct 2024
    Dr Harry has over 25 years experience in executive management of companies in the biotechnology, diagnostic and pharmaceutical sectors. She is a CEO with experience in growing companies from start-up to commercialisation. Dr Harry is currently a Non-Executive Director of Neuren Pharmaceuticals Limited (ASX: NEU) and Aeris Environmental Ltd (ASX: AEI) and is a member of the IP Committee of the Childrens Medical Research Institute.
    Mr Michael Anton Aicher Executive Director - US Operations May 2014
    Mr Aicher has over 30 years of industry experience and was CEO and founder of National Genetics Institute NGI which was acquired by Laboratory Corporation of America,Inc.LabCorp in 2000.Mr Aicher led LabCorp's Esoteric Business Units, which generated more than $1 billion in annual revenue. Prior to NGI, Mr. Aicher served in several executive leadership roles at Central Diagnostics Laboratory. He currently serves as a director on boards of Roswell Biotechnologies,Techcyte and CytoBay.
    Dr Neil Gunn Interim CEO Non-Executive Director Apr 2024
    Mr Gunn has over 30 years of experience in medical devices and diagnostics. Most recently Dr Gunn was CEO of IDbyDNA, a metagenomics company based in the US that was acquired by Illumina in 2022. Prior to this he was the President of Roche Sequencing Solutions where he oversaw all aspects of the business and managed a team of approximately 900 people. His team developed and launched more than 20 products per year. Dr Gunn was also previously Vice President of Roche's Molecular Diagnostics business and was responsible for over 120 diagnostic product launches principally into the IVD clinical market.
    Ms Anne Nicole Lockwood Non-Executive Director Oct 2024
    Ms Lockwood, is currently a Non-Executive Director for the ASX-listed company Mayne Pharma and Chief Financial Officer for Planet Innovation. She brings finance and accounting as well as US operations experience gained from senior executive roles in healthcare and life science companies.
    Mr Karl David Pechmann Chief Financial OfficerChief Operating OfficerCompany Secretary Jun 2023
    -
    Mr Michael Sapountzis Company Secretary Feb 2025
    -
    Ms Allison Rossiter -- Sep 2024
    -
    Allison Rossiter --
    -
    Karl David Pechmann Chief Financial OfficerChief Operating OfficerCompany Secretary
    -
    Michael Sapountzis Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Asia Union Investments Pty Ltd 43,139,098 19.04%
    Hsbc Custody Nominees (Australia) Limited 39,532,373 17.45%
    UBS Nominees Pty Ltd 17,710,726 7.82%
    BNP Paribas Noms Pty Ltd 13,938,023 6.15%
    Citicorp Nominees Pty Limited 11,708,300 5.17%
    J P Morgan Nominees Australia Pty Limited 6,099,645 2.69%
    Mirrabooka Investments Limited 4,313,513 1.90%
    Capital Concerns Pty Limited <Logue Family Super Fund A/C> 4,032,191 1.78%
    Bnp Paribas Nominees Pty Ltd <Clearstream> 2,689,480 1.19%
    Braham Consolidated Pty Ltd 2,636,753 1.16%
    Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> 1,971,242 0.87%
    Asia Union Investments Pty Ltd i 1,809,937 0.80%
    BNP Paribas Nominees Pty Ltd <Agency Lending A/C> 1,671,273 0.74%
    Idollink Pty Ltd <Mckeith Super Fund A/C> 1,596,596 0.70%
    Riddler Family Investments Pty Ltd 1,406,013 0.62%
    HSBC Custody Nominees (Australia) Limited i 1,291,701 0.57%
    Mr Michael Andrew Whiting & Mrs Tracey Anne Whiting <Whiting Family S/F A/C> 1,237,854 0.55%
    Quickinvest Pty Ltd <Quickinvest Staff S/F A/C> 1,173,384 0.52%
    Juleyu Pty Ltd <Phillip Isaacs S/F A/C> i 993,020 0.43%
    Mr Alistair David Strong 900,000 0.40%

    Profile

    since

    Note